SOPHiA GENETICS

Democratizing Data-Driven Medicine, Together!

Founded 2011

Switzerland 509 employees IPO Total: $573.70M Biotechnology, Pharmaceutical

General Information

Company Name SOPHiA GENETICS

Founded Year 2011

Location

Switzerland

Founders / Decision Makers

Employees 509

Industries Biotechnology, Pharmaceutical

Funding Stage IPO

Business Model B2B, SaaS, Platform

Revenue Model Subscription, Usage Based, Service Fee

Hiring 24 roles posted in the month to 7 Nov 2026

Offices as of Nov 2026

Rolle, Switzerland Boston, United States Bidart, France

Social

BounceWatch is an independent company data service, not affiliated with SOPHiA GENETICS. To contact SOPHiA GENETICS, visit sophiagenetics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SOPHiA GENETICS compare?

A PDF of SOPHiA GENETICS and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SOPHiA GENETICS soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

From the desk

Is SOPHiA GENETICS on your competitive set?

Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.

Book a 7-day Readout

Discover More

Switzerland Market

Market Signals All Companies

Biotechnology

Industry Signals All Companies in Switzerland

SOPHiA GENETICS Alternatives

All Signals Trend Reports

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Nov 05, 2026

SOPHiA GENETICS sponsored HerCode’s hackathon at ETH Zürich, with Shubham Nayyar opening the event.

In The News Nov 03, 2026

Featured on Yahoo Finance: SOPHiA GENETICS Q3 Earnings Call Highlights

In The News Nov 03, 2026

Featured on Yahoo Finance: SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates

Actively Hiring Nov 03, 2026

Hiring for 24 positions in the last 30 days.

Revenue Metrics Nov 03, 2026

Sophia Genetics' revenue was better than expected.

Growth Metrics Nov 03, 2026

The company improved adjusted EBITDA loss by 31% year-over-year to $6.1 million and signed 30 new genomics customers in Q3.

+5 more signals in last 30 days

SOPHiA GENETICS a competitor of yours? Have our desk watch it

AI Insight

Bounce Watch AI

7 hours ago

SOPHiA GENETICS has demonstrated significant strategic momentum in Q3 2026, launching key AI-powered product innovations like SOPHiA DDM™ Digital Twins and SOPHiA DDM™ for Multimodal, while securing a major partnership with Myriad Genetics and a new customer, Trillium Health Partners. Despite reporting a Q3 loss, the company exceeded revenue estimates and significantly improved its adjusted EBITDA loss, indicating a strong path towards operational efficiency and continued market penetration through product expansion and strategic collaborations.

Signal Types

Product Launch Financial Performance Partnership Customer Acquisition Hiring

Strategic Labels

AI Innovation Market Penetration Operational Efficiency

Next Move: Expansion

Impact: 8/10

Ideal For: Growth Equity Investors — Public Healthcare Tech

About SOPHiA GENETICS

SOPHiA GENETICS, founded in 2011 and headquartered in Switzerland, has positioned itself at the forefront of the precision medicine field with its innovative platform, SOPHiA DDM™. The technology distills complex data into actionable insights that empower clinicians, researchers, and biopharma to enhance diagnosis and treatment of cancer and rare disorders. By leveraging AI, the platform creates a collective intelligence that grows with the data input from its community.

The company’s mission, encapsulated in its slogan, "Democratizing Data-Driven Medicine, Together!", reflects its focus on expanding access to precision medicine globally. The recent $50.00M Post IPO debt investment led by Perceptive Advisors in May 2024, underscores investor confidence in the company’s capabilities and future growth trajectory.

SOPHiA GENETICS stands out in the healthcare landscape for its commitment to ensuring equitable access to precision medicine, driven by a passionate and purpose-led team. As it continues to grow, the company's influence in reshaping patient care is poised to expand significantly.

Business keywords: Data-Driven Medicine, Precision Medicine, Cloud-based SaaS Platform, Genomics, Bioinformatics, Multimodal Data Analysis, Deep Learning, Oncology, Cancer Diagnosis, Liquid Biopsy, ctDNA, Global Data Access

Services & Products

SOPHiA DDM™ Platform

Genomics Analysis

Radiomics Analysis

Multimodal Analysis

Professional Services

AI-powered Data Insights

Target Customers

Oncologists Radiologists Pathologists Geneticists Lab Technicians Bioinformaticians BioPharma Companies Healthcare Institutions

Funding Rounds & Investors (12)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Equity	$50.00M	-		01 Jun 2026
Post-IPO Debt	$50.00M	1	Perceptive Advisors	01 May 2024
IPO	$234.00M	-		01 Jul 2021
Series F	$110.00M	8	Swisscom Ventures, Generation Investment Management +6	01 Oct 2020
Series E	€67.00M	4	Balderton Capital, Generation Investment Management +2	01 Jan 2019
Series D	$30.00M	4	360 Capital, Balderton Capital +2	01 Sep 2017
Series C	$15.00M	1	Marc Coucke	01 Dec 2015
Series B	$13.80M	3	Swisscom Ventures, Invoke Capital Partners +1	01 Jul 2014
Series A	Fr.3.80M	-		01 Dec 2013
Seed	Fr.100.00K	1	Fondation FIT	01 Nov 2011

View All 12 Funding Rounds

Latest News

View All

SOPHiA GENETICS SA (SOPH) Stock Price, News, Quote & History

Yahoo! Finance Canada Nov 04, 2026

SOPHiA GENETICS Q3 Earnings Call Highlights

Yahoo Finance Nov 03, 2026

Earnings Call: SOPHiA GENETICS verfehlt EPS-Erwartungen im Q3 2026 – Aktie gibt vorbörslich nach

Investing.com Deutsch Nov 03, 2026

SOPHiA GENETICS: Umsatz im dritten Quartal steigt um 25%, bereinigter EBITDA-Verlust geht zurück

Securities.io Nov 03, 2026

SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates

Yahoo Finance Nov 03, 2026

Sophia Genetics: EPS verfehlt Schätzungen um 0,06 $ - Umsatz besser als erwartet

Investing.com Deutsch Nov 03, 2026

SOPHiA GENETICS Alternatives & Competitors

View All Alternatives

SOPHiA GENETICS vs

Enable Medicine United States

Spatial and multimodal insights powered by AI for your next therapeutic breakthrough.

Acquired

15 employees

Biotechnology, Pharmaceutical

SOPHiA GENETICS vs

Foresight Diagnostics (a Natera company) United States

Precision medicine company dedicated to improving the lives of cancer patients through improved canc...

Acquired

112 employees

Biotechnology, Health Care

SOPHiA GENETICS vs

Diatech Pharmacogenetics Italy

Leader in the development, production and sales of pharmacogenetics tests for cancer precision medic...

Private Equity

76 employees

Biotechnology, Health Care

View all alternatives

FAQ About SOPHiA GENETICS

Democratizing Data-Driven Medicine, Together!

SOPHiA GENETICS was founded in 2011.

SOPHiA GENETICS is headquartered in Switzerland. As of Nov 2026, it also has offices in Rolle, Switzerland, Boston, United States and Bidart, France.

SOPHiA GENETICS operates in Biotechnology and Pharmaceutical. Its work centres on Data-Driven Medicine, Precision Medicine, Cloud-based SaaS Platform and Genomics. Its customers include Oncologists, Radiologists and Pathologists.

SOPHiA GENETICS has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Usage Based and Service Fee.

SOPHiA GENETICS has approximately 509 employees.

SOPHiA GENETICS has completed 12 funding rounds, raising a total of $573.70M. The latest funding stage is IPO.

SOPHiA GENETICS offers: SOPHiA DDM™ Platform, Genomics Analysis, Radiomics Analysis, Multimodal Analysis, Professional Services, AI-powered Data Insights.

Top alternatives and competitors to SOPHiA GENETICS include Enable Medicine, Foresight Diagnostics (a Natera company), Diatech Pharmacogenetics, LCM Genect, Seven Bridges. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

SOPHiA GENETICS and Enable Medicine are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SOPHiA GENETICS, https://bouncewatch.com/company/sophia-genetics, updated 8 November 2026. When citing, please name BounceWatch and link this page.

SOPHiA GENETICS

General Information

Discover More

What changed at SOPHiA GENETICS recently?

AI Insight

About SOPHiA GENETICS

Services & Products

Target Customers

Funding Rounds & Investors (12)

Latest News

SOPHiA GENETICS Alternatives & Competitors

FAQ About SOPHiA GENETICS